Ostrom QT, Price M, Neff C, Cioffi G, Waite KA, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol. 2022. https://doi.org/10.1093/neuonc/noac202.

Article  PubMed  PubMed Central  Google Scholar 

Pellerino A, Caccese M, Padovan M, Cerretti G, Lombardi G. Epidemiology, risk factors, and prognostic factors of gliomas. Clin Transl Imaging. 2022;10(5):467–75.

Article  Google Scholar 

Tavanaei R, Akhlaghpasand M, Tavanaei D, Khannejad S, Hosseinpoor M, Sohrabi M-R, et al. Epidemiology of malignant gliomas in Iran: first report of Iranian national population-based cancer registry, 2009–2017. J Neurosurg. 2024. https://doi.org/10.3171/2024.4.JNS2470.

Article  PubMed  Google Scholar 

Ostrom QT, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol. 2016. https://doi.org/10.1093/neuonc/now207.

Article  PubMed  PubMed Central  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer Journal Clin. 2021;71(3):209–49.

Google Scholar 

Shergalis A, Bankhead A, Luesakul U, Muangsin N, Neamati N. Current challenges and opportunities in treating glioblastoma. Pharmacol Rev. 2018;70(3):412–45.

Article  PubMed  PubMed Central  CAS  Google Scholar 

van den Bent MJ, Geurts M, French PJ, Smits M, Capper D, Bromberg JEC, et al. Primary brain tumours in adults. The Lancet. 2023;402(10412):1564–79.

Article  Google Scholar 

White J, White MPJ, Wickremesekera A, Peng L, Gray C. The tumour microenvironment, treatment resistance and recurrence in glioblastoma. J Transl Med. 2024;22(1):1–14.

Article  Google Scholar 

Goenka A, Tiek D, Song X, Huang T, Hu B, Cheng S-Y. The many facets of therapy resistance and tumor recurrence in glioblastoma. Cells. 2021;10(3):484.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nicholson JG, Fine HA. Diffuse glioma heterogeneity and its therapeutic implications. Cancer Discov. 2021;11(3):575–90.

Article  PubMed  CAS  Google Scholar 

Lucchini S, Constantinou M, Marino S. Unravelling the mosaic: epigenetic diversity in glioblastoma. Mole Oncol. 2024. https://doi.org/10.1002/1878-0261.13706.

Article  Google Scholar 

Sharma P, Aaroe A, Liang J, Puduvalli VK. Tumor microenvironment in glioblastoma: current and emerging concepts. Neuro-Oncol Adv. 2023;5(1):vdad009.

Article  Google Scholar 

Sharma S, Chepurna O, Sun T. Drug resistance in glioblastoma: from chemo-to immunotherapy. Cancer Drug Resist. 2023;6(4):688.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dong X. Current strategies for brain drug delivery. Theranostics. 2018;8(6):1481.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pardridge WM. Drug transport across the blood–brain barrier. J Cereb Blood Flow Metab. 2012;32(11):1959–72.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li Y, Yuan H, Yang K, Xu W, Tang W, Li X. The structure and functions of P-glycoprotein. Curr Med Chem. 2010;17(8):786–800.

Article  PubMed  CAS  Google Scholar 

Zhao M, van Straten D, Broekman MLD, Préat V, Schiffelers RM. Nanocarrier-based drug combination therapy for glioblastoma. Theranostics. 2020;10(3):1355.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sa P, Singh P, Dilnawaz F, Sahoo SK. Application of therapeutic nanoplatforms as a potential candidate for the treatment of CNS disorders: challenges and possibilities. Curr Pharm Des. 2022;28(33):2742–57.

Article  PubMed  CAS  Google Scholar 

Lu C-T, Zhao Y-Z, Wong HL, Cai J, Peng L, Tian X-Q. Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomed. 2014. https://doi.org/10.2147/IJN.S61288.

Article  Google Scholar 

Sahoo L, Paikray SK, Tripathy NS, Fernandes D, Dilnawaz F. Advancements in nanotheranostics for glioma therapy. Naunyn-Schmiedeberg’s Archiv Pharmacol. 2024. https://doi.org/10.1007/s00210-024-03559-w.

Article  Google Scholar 

Dilnawaz F, Sahoo SK. Therapeutic approaches of magnetic nanoparticles for the central nervous system. Drug Discovery Today. 2015;20(10):1256–64.

Article  PubMed  CAS  Google Scholar 

Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood–brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023;8(1):217.

Article  PubMed  PubMed Central  Google Scholar 

Dilnawaz F, Singh A, Sahoo SK. Magnetic nanoparticles: a versatile system for therapeutics and imaging. Nanotechnol Health Care. 2012;20:215.

Google Scholar 

Wadhwa K, Chauhan P, Kumar S, Pahwa R, Verma R, Goyal R, et al. Targeting brain tumors with innovative nanocarriers: bridging the gap through the blood-brain barrier. Oncol Res. 2024;32(5):877.

Article  PubMed  PubMed Central  Google Scholar 

Zhang X, Sun X, Guo C, Li J, Liang G. Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization. Am J Physiol Cell Physiol. 2024;326(1):C252–68.

Article  PubMed  Google Scholar 

Wong KK, Banham AH, Yaacob NS, Nur Husna SM. The oncogenic roles of TRPM ion channels in cancer. J Cell Physiol. 2019;234(9):14556–73.

Article  PubMed  CAS  Google Scholar 

Santoni G, Maggi F, Morelli MB, Santoni M, Marinelli O. Transient receptor potential cation channels in cancer therapy. Med Sci. 2019;7(12):108.

CAS  Google Scholar 

Hantute-Ghesquier A, Haustrate A, Prevarskaya N. Lehen’kyi Vy. TRPM Fam Chann Cancer Pharmaceut. 2018;11(2):58.

Google Scholar 

Chen Z, Xie H, Liu J, Zhao J, Huang R, Xiang Y, et al. Roles of TRPM channels in glioma. Cancer Biol Ther. 2024;25(1):2338955.

Article  PubMed  PubMed Central  Google Scholar 

Chinigò G, Castel H, Chever O, Gkika D. TRP channels in brain tumors. Front Cell Develop Biol. 2021;9: 617801.

Article  Google Scholar 

Guo J, Shan C, Xu J, Li M, Zhao J, Cheng W. New insights into TRP ion channels in stem cells. Int J Mol Sci. 2022;23(14):7766.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Zhang C, Moore LM, Li X, Yung WKA, Zhang W. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neuro Oncol. 2013;15(9):1114–26.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li L, Yu R, Cai T, Chen Z, Lan M, Zou T, et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int Immunopharmacol. 2020;88: 106939.

Article  PubMed  CAS  Google Scholar 

Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol. 2008;66(1):1–9.

Article  PubMed  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–51.